BGM Group Ltd. (NASDAQ: BGM) is a China-based company specializing in the development, manufacture, marketing, and sale of pharmaceutical products, including licorice products, oxytetracycline, traditional Chinese medicine derivatives (TCMD), heparin, sausage casings, and fertilizers. Operating primarily within the domestic market, BGM Group is committed to producing safe, effective, and affordable pharmaceutical ingredients that elevate healthcare standards globally. The company's vision is to lead in pharmaceutical innovation, contributing to a healthier and more connected global community.
BGM Group's strategic focus encompasses AI applications, intelligent robots, algorithmic computing power, cloud computing, and biopharmaceuticals. The company leverages big data mining and AI Agent technology through platforms like Du Xiao Bao and Bao Wang to provide comprehensive AI solutions and intelligent robot services for insurance companies, brokers, and consumers. These services cover key scenarios such as sales and marketing, underwriting assessment, claims processing, and customer service. In the biopharmaceutical sector, BGM integrates AI-assisted decision-making into production and manufacturing processes, enhancing supply chain optimization, process efficiency, and market trend prediction.
As of July 8, 2025, BGM Group's stock is trading at $10.00 per share. The company has a market capitalization of approximately $948.89 million, with 97.22 million shares outstanding. In the fiscal year ending September 30, 2024, BGM reported annual sales of $25.1 million and a net income of -$1.44 million. The company's financial strategy includes leveraging AI technologies to enhance operational efficiency and exploring new revenue streams through strategic acquisitions.
BGM Group's product portfolio includes oxytetracycline APIs, licorice preparations, crude heparin sodium, and fertilizers. The company operates through three segments: Oxytetracycline & Licorice Products and TCMD, Fertilizer, and Heparin Products and Sausage Casing. In the fiscal year ending September 30, 2024, the Oxytetracycline & Licorice Products and TCMD segment generated $21.96 million in sales, the Heparin Products and Sausage Casing segment generated $2.23 million, and the Fertilizer segment generated $906,000.
BGM Group integrates AI-assisted decision-making into its production and manufacturing processes, enhancing supply chain optimization, process efficiency, and market trend prediction. The company's proprietary platforms, Du Xiao Bao and Bao Wang, utilize big data mining and AI Agent technology to provide comprehensive AI solutions and intelligent robot services for the insurance industry. These platforms analyze consumer data, build consumer profiles, accurately predict insurance needs, and offer highly customized services.
The leadership team at BGM Group includes:
- Chen Xin, Chief Executive Officer (CEO) since May 30, 2024.
- Hai Ping Shi, Director of Finance/Chief Financial Officer (CFO) since June 14, 2020.
- Zhan Chang Xin, Chairman of the Board since February 6, 2019.
- Ming Jing, Director/Board Member since April 7, 2020.
- Ding Qian Liu, Director/Board Member since June 8, 2023.
- Song Gao, Director/Board Member since July 12, 2023.
In February 2025, BGM Group announced changes to its board of directors, marking the company's entry into a new phase of technological transformation and sustainable growth. Mr. Zhanchang Xin tendered his resignation and stepped down from his role as Chairman, effective March 1, 2025.
BGM Group operates in the competitive pharmaceutical industry, facing competition from companies such as Organigram (OGI), Rezolute (RZLT), Context Therapeutics (CNTX), DiaMedica Therapeutics (DMAC), Atossa Therapeutics (ATOS), Shattuck Labs (STTK), Mersana Therapeutics (MRSN), Skye Bioscience (SKYE), Amylyx Pharmaceuticals (AMLX), and Eli Lilly and Company (LLY). These companies are part of the "pharmaceutical preparations" industry and compete in various segments of the market.
BGM Group has engaged in significant strategic collaborations and partnerships to strengthen its market position and innovation capacity. In December 2024, the company completed the acquisition of the intelligent platform of AIX Inc., marking its official entry into AI intelligent technology and financial/insurance services. This acquisition opens new opportunities for the integrated development of healthcare, pharmaceuticals, and insurance on a global scale.
BGM Group's strategic considerations include leveraging its AI capabilities to enhance operational efficiency and product offerings, differentiating itself from competitors through technological innovation, and expanding its market presence in the pharmaceutical and insurance sectors. The company's integration of AI into its operations provides a distinct competitive advantage in the industry.
Looking ahead, BGM Group aims to continue its strategic roadmap by further integrating AI technologies into its operations, exploring new market opportunities in the pharmaceutical and insurance sectors, and strengthening its position as a leader in pharmaceutical innovation. The company's current strengths in AI and biopharmaceuticals position it well to achieve these future objectives.
For more information, visit BGM Group's official website.
Stock market information for BGM Group Ltd. (BGM)
- BGM Group Ltd. is a equity in the USA market.
- The price is 10.0 USD currently with a change of -0.03 USD (-0.00%) from the previous close.
- The latest open price was 9.9 USD and the intraday volume is 52608.
- The intraday high is 10.55 USD and the intraday low is 9.67 USD.
- The latest trade time is Tuesday, July 8, 00:15:00 UTC.
